74965-87-0

Basic information

• Product Name: 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-(phenylacetyl)-
• CAS NO: 74965-87-0
• Molecular Formula: C14H14O5
• Molecular Weight: 262.262
• Mol File: 74965-87-0.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-(phenylacetyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-(phenylacetyl)-(74965-87-0)
• EPA Substance Registry System: 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-(phenylacetyl)-(74965-87-0)

Safety Data

• Hazardous Substances Data: 74965-87-0(Hazardous Substances Data)

Upstream product

• 103-82-2 phenylacetic acid 
• 2033-24-1 cycl-isopropylidene malonate 
• 3740-52-1 2-(2-nitrophenyl)acetic acid 
• 103-80-0 phenylacetyl chloride 
• 22751-23-1 (2-nitrophenyl)acetyl chloride 

Downstream Products

• 820223-86-7 (S)-3-amino-4-phenylbutanoic acid 
• 166023-31-0 tert-butyl (3R)-3-amino-4-phenylbutanoate 
• 120686-17-1 (S)-3-amino-4-phenylbutyric acid tert-butyl ester 
• 140210-06-6 (S)-3-Amino-4-phenyl-butyric acid benzyl ester 
• 87512-35-4 tert-butyl 3-amino-4-phenylbut-2-enoate 
• 81803-86-3 N-acetyl-2-(phenylacetoacetyl)aniline 
• 81803-89-6 N-acetyl-2-benzylindole 
• 37779-49-0 methyl 3-oxo-4-phenylbutanoate 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs

On the basis of structural features, binding mode, and structure-activity relationship studies of two pyrimidine-derived non-nucleoside reverse-transcriptase inhibitors, DABOs, and diaryl pyrimidines, a novel class of 1,2,6-thiadiazine-1,1-dione derivatives were rationally designed using the strategies of bioisosterism and molecular hybridization, synthesized, and evaluated for their anti-HIV activity in MT4 cell cultures. Three compounds were found to have moderate activity against HIV-1 replication with EC50 values ranging from 23 to 32 μm. To further confirm the binding target, compound IIg was selected to conduct an HIV-1 reverse-transcriptase inhibitory assay. In addition, preliminary structure-activity relationship analysis among the newly synthesized compounds was discussed, and the binding mode of the active compound IIg was rationalized by molecular docking and physicochemical studies.

CARBON MONOXIDE-RELEASING MOLECULES AND THERAPEUTIC APPLICATIONS THEREOF

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.